GI Dynamics is Now Morphic Medical. Learn More.

Our data demonstrate that EndoBarrier is highly effective in people with refractory diabesity, with maintenance of significant improvement three years after removal in 77% of cases.  

Significant effects of DJBL treatment on NAFLD fibrosis and APRI score further suggests protective effects of DJBL on liver-related morbidity and mortality in patients with obesity and T2DM.

People with obesity commonly face a pervasive, resilient form of social stigma. They are often subject to discrimination in the workplace as well as in educational and healthcare settings. Research indicates that weight stigma can cause physical and psychological harm, and that affected...

EndoBarrier was highly effective in this setting in patients with advanced diabetes and obesity. Given the high cardiovascular and microvascular risk of these patients, benefits might outweigh risks. As an endoscopic procedure it is relatively simple and non-invasive. Early removal rates require...

The aim of this study was therefore to investigate the safety, feasibility and effectiveness of early (4-month) reimplantation of the DJBL in patients who show an early relapse in BMI and HbA1c after DJBL explantation.

In addition to reducing the requirement for insulin and a liver fat biomarker, EndoBarrier treatment reduced 10-year CVD risk by clinically useful amounts in patients with poorly controlled diabetes and obesity. These data suggest that EndoBarrier treatment in 100 patients could prevent between 8...

Obesity associated with diabetes mellitus is a significant worldwide problem associated with considerable health care costs. Whilst surgical intervention is effective, it is invasive, costly and associated with complications. This study aims to evaluate the safety and efficacy of the EndoBarrier®,...

This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population.

End-OSA trial (ISRCTN:33788132) is an NIHR sponsored research trial, to assess the extent to which patients with type 2 diabetes/pre-diabetes, obesity(BMI 30-45Kg/m²) and moderate OSA requiring CPAP are able to discontinue CPAP following EndoBarrier related weight loss.

Our data demonstrate EndoBarrier as highly effective in patients with refractory diabesity. Maintenance of improvement after EndoBarrier removal was achieved in 68%. There were high patient satisfaction levels and an acceptable safety profile. As endoscopy units are ubiquitous, our service could...